SCHEMBL30405599

SCHEMBL30405599

Nc1ncnc2c1c(I)nn2-c1cc(Cl)ncn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.42
▸ CSNK1A1 P48729 3/20 0.42
▸ CSNK1D P48730 3/20 0.42
▸ CDK5 Q00535 3/20 0.42
▸ CLK4 Q9HAZ1 3/20 0.42
▸ DYRK3 O43781 2/20 0.42
▸ CDK1 P06493 2/20 0.42
▸ ROS1 P08922 2/20 0.42
▸ RPS6KB1 P23443 2/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ CLK2 P49760 2/20 0.42
▸ IRAK1 P51617 2/20 0.42
▸ DYRK1A Q13627 2/20 0.42
▸ NTRK3 Q16288 2/20 0.42
▸ SLK Q9H2G2 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ LCK P06239 2/20 0.42
▸ FYN P06241 2/20 0.42
▸ PRKACA P17612 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20553262 1.00 SRC (0.42) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL4825966 0.80 SRC (0.43) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL27587387 0.74 SRC (0.45) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL23150443 0.73 JAK2 (0.42) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL401337 0.72 SRC (0.45) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL24096486 0.71 SRC (0.50) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL22748995 0.70 DYRK3 (0.51) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL22430336 0.70 ADK (0.51) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL26809032 0.70 DYRK3 (0.55) SRCCSNK1A1CSNK1DCDK5CLK4
SCHEMBL130592 0.68 SRC (0.50) SRCCSNK1A1CSNK1DCDK5CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168002-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS Revolution Medicines, Inc. (US) 2023-04-26 — — EP disclosed
Send feedback